Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02121938 · ClinicalTrials.gov registry record
Dynamics of the Microbiome in the Premature Infant
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 30
- Enrollment target
NCT02121938: Completed study, sponsored by Duke University.
NCT02121938 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02121938 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
The purpose of the study is to describe the dynamics of the microbiome in the premature infant as a means to adapt the premature infant gut to affect better health outcomes.
Primary Outcome
The investigators immediate goal is to identify antigens of the preterm infant microbiome that are recognized by natural and adaptive antibodies and determine how mucosal and serologic antibody responses alter the dynamics of secondary intestinal colonization.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-04 |
| Est. Completion | 2016-06 |
What the finished NCT02121938 record still lists
NCT02121938 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02121938 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02121938 about?
NCT02121938 is a clinical study titled "Dynamics of the Microbiome in the Premature Infant". The purpose of the study is to describe the dynamics of the microbiome in the premature infant as a means to adapt the premature infant gut to affect better health outcomes.
What is the current status of trial NCT02121938?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2014-04. Estimated completion is 2016-06.
Who is sponsoring clinical trial NCT02121938?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia